Daewoong Therapeutics provides CDO/CRO services based on Korea's best CMC R&D/licensing experience and excellent human resources pool.

Since its establishment in Feb 2019, Daewoong Therapeutics performed a number of technology transfers for incrementally modified drugs. Our pioneering product, DWRX1004, was approved for market release in April 2022 and is projected to raise more than 30 billion KRW in 2023 sales.

Our team of veteran-level professionals with decades of industrial experience are highly experienced in meeting our clients’ needs. From small molecule compounds to peptides, ophthalmic solutions, long acting injectables and other drug repurposing and repositioning work, we can help with your desired upgrade.